Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...